Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.00
+$0.01 · +0.50%
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Previous close
$2.00
+$0.01 · +0.50%
Regular session · ET · Market data may be delayed.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Day range
Current $2.00
52-week range
Current $2.00
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Sentiment
59
Mixed
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Day range
Current $2.00
52-week range
Current $2.00
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | 6.27M USD | 2.81M USD | 2.77M USD |
| Selling, general, and administrative | 1.56M USD | 1.54M USD | 1.01M USD |
| Operating expenses | 7.82M USD | 4.35M USD | 3.78M USD |
| Operating income | −7.82M USD | −4.35M USD | −3.78M USD |
| Net income | −8.99M USD | −30.36M USD | −3.78M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.50
225.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
